<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797055</url>
  </required_header>
  <id_info>
    <org_study_id>MD2009.04</org_study_id>
    <nct_id>NCT01797055</nct_id>
  </id_info>
  <brief_title>Apotransferrin in Atransferrinemia</brief_title>
  <official_title>Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanquin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atransferrinemia is a very rare disorder, which is caused by a deficiency of the protein
      transferrin. No regular treatment is available for these patients. The objective of this
      study is to investigate the pharmacokinetics, efficacy and safety of Apotransferrin
      replacement therapy in atransferrinemia patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobulin</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>first infusion</time_frame>
    <description>serum transferrin levels measured on several time points before and after infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>iron overload in organs</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>transferrin levels</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>adverse drug reactions</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Congenital Atransferrinemia</condition>
  <arm_group>
    <arm_group_label>human apotransferrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous apotransferrin every 4-8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human apotransferrin</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>human apotransferrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of atransferrinemia, defined as serum levels of transferrin
             below 40 mg/dl

          -  Informed consent

        Exclusion Criteria:

          -  Known with allergic reactions against human plasma or plasma products

          -  Having detectable anti-immunoglobulin A antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C R Diaz de Heredia Rubio, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d'Hebron, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K Moser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>klinikum Aschaffenburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Biondi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO San Gerardo Monza, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilona Kleine Budde, PhD</last_name>
    <email>i.kleinebudde@sanquin.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Titia Mulders, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Moser, MD</last_name>
    </contact>
    <investigator>
      <last_name>K Moser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Biondi, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Biondi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C R Diaz de Heredia Rubio, PhD, MD</last_name>
    </contact>
    <investigator>
      <last_name>C R Diaz de Heredia Rubio, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transferrin</keyword>
  <keyword>anemia</keyword>
  <keyword>iron overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metal Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

